,trastuzumab deruxtecan
astrazeneca,roche,daiichi sankyo
['destiny,breast,03', 'breast', 'destinybreast03']
the #oncoalerttoptweet day 2 #asco22 tweet #destinybreast03 safety update by after median time on treatment 6.9mon tdm1 vs 16.1mon tdxd 10.9% ild, mostly grade 1-2
no grade 4 best, 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??